Phosphorylation Region of the Yeast Plasma-membrane H+-ATPase
ROLE IN PROTEIN FOLDING AND BIOGENESIS*

Natalie D. DeWittDagger , Carlos F. Tourinho dos Santos§, Kenneth E. Allen, and Carolyn W. Slayman

From the Departments of Genetics and Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut 06510

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Mutations at the phosphorylation site (Asp-378) of the yeast plasma-membrane H+-ATPase have been shown previously to cause misfolding of the ATPase, preventing normal movement along the secretory pathway; Asp-378 mutations also block the biogenesis of co-expressed wild-type ATPase and lead to a dominant lethal phenotype. To ask whether these defects are specific for Asp-378 or whether the phosphorylation region as a whole is involved, alanine-scanning mutagenesis has been carried out to examine the role of 11 conserved residues flanking Asp-378. In the sec6-4 expression system (Nakamoto, R. K., Rao, R., and Slayman, C. W. (1991) J. Biol. Chem. 266, 7940-7949), the mutant ATPases displayed varying abilities to reach the secretory vesicles that deliver plasma-membrane proteins to the cell surface. Indirect immunofluorescence of intact cells also gave evidence for a spectrum of behavior, ranging from mutant ATPases completely arrested (D378A, K379A, T380A, and T384A) or partially arrested in the endoplasmic reticulum to those that reached the plasma membrane in normal amounts (C376A, S377A, and G381A). Although the extent of ER retention varied among the mutants, the endoplasmic reticulum appeared to be the only secretory compartment in which the mutant ATPases accumulated. All of the mutant proteins that localized either partially or fully to the ER were also malfolded based on their abnormal sensitivity to trypsin. Among them, the severely affected mutants had a dominant lethal phenotype, and even the intermediate mutants caused a visible slowing of growth when co-expressed with wild-type ATPase. The effects on growth could be traced to the trapping of the wild-type enzyme with the mutant enzyme in the ER, as visualized by double label immunofluorescence. Taken together, the results indicate that the residues surrounding Asp-378 are critically important for ATPase maturation and transport to the cell surface.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In eukaryotic cells, the first step in the biogenesis of plasma membrane proteins takes place in the endoplasmic reticulum, where there is an elaborate machinery to ensure correct protein folding and integration into the lipid bilayer (1, 2). In recent years, several genetic diseases have been traced to mutations that damage the ability of particular proteins to interact properly with this biosynthetic machinery (3). Perhaps the best known example is cystic fibrosis, in which the deletion of a single phenylalanine residue (Phe-508) from a plasma-membrane chloride channel known as CFTR1 leads to defective folding of the channel protein and retention in the ER (4-6). Similarly, familial hypercholesterolemia, a disease characterized by elevated plasma low density lipoprotein cholesterol and an increased risk of premature coronary artery disease, can arise from amino acid substitutions that cause ER retention of the low density lipoprotein receptor (7-9).

These observations make it important to understand the factors that contribute to the proper folding of plasma membrane proteins as well as the quality control mechanisms that prevent malfolded proteins from being transported to the cell surface. The budding yeast Saccharomyces cerevisiae can serve as a good model organism for such studies because of the increasingly detailed knowledge of its secretory system (10). In the work to be described below, we have focused on the yeast plasma membrane H+-ATPase, which is encoded by the PMA1 gene and comprises ~10% of total plasma-membrane protein (11, 12). Based on hydropathy plots and trypsinolysis studies, the ATPase is thought to contain 10 transmembrane segments, four at the N-terminal end and six at the C-terminal end of the molecule; both the N and C termini are exposed at the cytoplasmic side of the membrane (13).

As with CFTR (14) and the low density lipoprotein receptor (9), folding of the yeast PMA1 ATPase can be disrupted by a single amino acid substitution. This phenomenon was first observed during mutational studies of Asp-378, a residue conserved in all P-type ATPases. Asp-378 lies near the beginning of the central cytoplasmic loop and is phosphorylated by ATP to form a high energy beta -aspartyl phosphate intermediate; thus, it plays an essential role in the reaction cycle. Strikingly, replacement of Asp-378 by Asn, Ser, or Glu was found to cause intracellular accumulation of the mutant protein, blocking the biogenesis of co-expressed wild-type ATPase and giving rise to a dominant lethal phenotype (15-17). More recently, biochemical studies have shown that, although the D378N protein appears to be integrated into the ER lipid bilayer, it is poorly folded and severely impaired in ligand binding (18).

Because Asp-378 is a key player in catalysis, it could conceivably play a special role in folding and biogenesis. On the other hand, the entire region surrounding the phosphorylation site could be required for successful folding and transit through the secretory pathway. It therefore seemed worthwhile to explore the structural and functional role of residues throughout the phosphorylation region of the ATPase. With this goal in mind, we have conducted an alanine scan of 11 conserved amino acids that flank Asp-378. Each of the mutant proteins has been examined for expression, folding, subcellular location, enzymatic activity, and effect on trafficking of wild-type ATPase. The results indicate that most of the mutations, which cluster at the predicted site of a beta -turn, cause structural defects resulting in ER retention and dominant lethality. We conclude that the local region surrounding D378A is critically important for proper folding and interaction with the secretory machinery. In addition, our results show that the principal quality control step for the ATPase is located early in the secretory pathway: misfolded ATPases accumulate in the ER, but once they bypass the ER quality control machinery, they move to the plasma membrane without detectable accumulation in the Golgi.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Yeast Strains-- NY605 (MATa; ura3-52; leu2-3, 112; GAL2) was kindly provided by P. Novick. SY4 (MATa; ura3-52; leu2-3, 112; his4-619; GAL1::PMA1::URA3; sec6-4ts, GAL2) is isogenic with NY605, and was described previously by Nakamoto and co-workers (19). In this strain, the chromosomal copy of the PMA1 gene has been placed under control of the GAL1 promoter (20). SY4 also contains the temperature-sensitive sec6-4 allele that blocks the last step of the secretory pathway: namely, the fusion of secretory vesicles with the plasma membrane. When transformed with the appropriate plasmid (see below), SY4 allows newly synthesized ATPase to be arrested in the secretory vesicles for study (19).

Plasmids Containing Epitope-tagged PMA1-- For ease in detecting the ATPase during biogenesis studies, two different epitope-tagged versions of PMA1 were constructed, containing either a 10-amino acid c-Myc epitope plus linking sequences (MTASEQKLISEEDLNDTS... . ) or a 9-amino acid HA epitope (MTYPYDVPDYADTS... . ) near the N terminus of the ATPase.2 As shown in Table I, the Myc-tagged and HA-tagged PMA1 genes were placed under control of the GAL1 promoter in plasmids YCpGAL1pr-PMA1-myc (centromeric; URA3) and YCpGAL1pr-PMA1-HA (centromeric; LEU2). The lithium acetate method (21) was used to transform the plasmids into NY605 cells to study the delivery of the ATPase to the plasma membrane. The tagged genes were also placed under heat-shock control in plasmid YCp2HSE-PMA1-myc (centromeric; LEU2). These plasmids were transformed into SY4 cells to study the early stages of ATPase biogenesis.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Centromeric plasmids used in this study

Site-directed Mutagenesis-- The polymerase chain reaction was used to introduce mutations into a subcloned StyI-BamHI fragment of PMA1, as described previously (22). To Myc-tag the mutant alleles and place them under heat-shock or GAL1 control, DNA fragments carrying the mutations were subcloned into the centromeric expression plasmids described above. The presence of the mutations in the final constructs was confirmed by automated DNA sequencing of the StyI-BamHI region.

Immunoblotting of Myc-tagged pma1 Mutants in Yeast Total Membranes-- Quantitative immunoblotting was carried out to measure the steady-state expression levels of Myc-tagged wild-type and mutant ATPases in total membranes. SY4 cells transformed with either the wild-type or a mutant version of YCp2HSE-PMA1-myc were grown on minimal medium containing 2% galactose at 23 °C, transferred to medium containing 2% glucose for 3 h, and then shifted to 39 °C for 30 min (19). After zymolyase treatment and Dounce homogenization of the cells, total membranes were isolated by differential centrifugation (18). An aliquot of membranes containing 10 µg of protein was precipitated with trichloroacetic acid, solubilized in loading buffer, subjected to SDS-PAGE, transferred to polyvinylidene difluoride membrane, and immunoblotted with rabbit anti-Myc polyclonal antibody (Medical and Biological Laboratories, Nagoya, Japan), followed by incubation with 125I-protein A and fluorography.

Immunofluorescence-- Subcellular structures containing Myc-tagged ATPase were visualized by indirect immunofluorescence using a modification of the method of Redding et al. (23). For these experiments, NY605 cells were transformed with YCpGAL1pr-PMA1-myc alone (mutant or wild-type version; URA plasmid) or YCpGAL1pr-PMA1-HA (wild-type PMA1 gene; LEU plasmid) in combination with YCpGAL1pr-PMA1-myc (mutant pma1 gene; URA plasmid). The transformed strains were grown at 30 °C in synthetic complete medium (24) lacking uracil (or uracil and leucine) and containing 4% raffinose, which was used as a carbon source to prevent glucose repression in the next step. At 1 OD/ml, the cells were shifted to medium with 4% galactose for 4 h to induce expression of the plasmid-encoded ATPase gene(s). Cells were fixed, treated with Zymolyase T-100, and permeabilized by Triton X-100 as described previously (23).

Fixed, permeabilized spheroplasts were stained for immunofluorescence essentially as described by Redding et al. (23), but with the addition of a blocking step in modified WT buffer, in which the dry milk and bovine serum albumin were replaced by 5% normal goat serum (Sigma). Four different primary antibodies were used: HA polyclonal (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan), diluted 1:100; Myc monoclonal 9E10.2 from ascites fluid (provided by H. Dohlman), diluted 1:100; Sec7 large domain polyclonal antibody (provided by R. Schekman; Ref. 25), diluted 1:150; and Kar2 polyclonal antibody (provided by M. Rose; Ref. 26), diluted 1:5000. Goat anti-rabbit FITC and goat anti-mouse Texas Red IgG (Jackson Immunoresearch, West Grove, Pa) served as fluorescent secondary antibodies and were diluted 1:100. For double labeling experiments, both primary antibodies were present during the initial incubation and both secondary antibodies were present during the subsequent incubation. To control for spurious cross-reactivity of the c-Myc and HA antibodies, uninduced cells were simultaneously fixed and stained with each set of antibodies. Cells were then stained with 4,6'-diamidino-2-phenylindole (Sigma), and mounted in Citifluor (Ted Pella, Redding, PA).

For fluorescence microscopy, cells were observed with a Nikon Microphot-FXA (Melville, NY) and photographed using Tmax 400 black-and-white film (Eastman Kodak Co.). For confocal microscopy, cells were observed on a Bio-Rad MRC-600 scanning confocal microscope using dual channel filters for simultaneous visualization of Texas Red and FITC fluorochromes. For all images, the slit width was set to provide an optical slice of <1 µm. The absence of nonspecific antibody binding was verified by examining uninduced controls using the same settings, and the absence of bleed-through, by confirming that the signal disappeared when viewed with single-wavelength filter blocks. Images were collected with Comos software (Bio-Rad) and modified by contrast stretching, application of pseudocolor, and merging, using Adobe Photoshop 4.0 (Adobe Systems Inc., San Jose, CA).

Isolation of Secretory Vesicles, ATPase Assay, and Limited Trypsinolysis-- Secretory vesicles were isolated from SY4 cells transformed with the wild-type or a mutant version YCp2HSE-PMA1-myc using a two-step discontinuous sucrose gradient (27). Assays of ATPase hydrolysis, ATP-dependent proton transport, and protein were carried out as described previously (17, 28), as were limited trypsinolysis experiments (18).

Genetic Tests of Dominance or Recessiveness-- To examine the genetic behavior of the various mutations, NY605 cells transformed with wild-type or mutant YCpGAL1-PMA1-myc plasmid were grown on synthetic medium lacking uracil and containing 2% glucose. Cells were diluted in water and tested for growth on solid medium, lacking uracil and containing either 2% glucose (wild-type gene expressed) or 2% galactose (both mutant and wild-type genes expressed). The plates were incubated at 30 °C for 42 h and photographed.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Definition of the Region to Be Studied-- As described above, a central goal of this work was to explore structure-function relationships in the phosphorylation region of PMA1, surrounding the site (Asp-378) at which the beta -aspartyl phosphate reaction intermediate is formed. To choose residues for study, sequences were aligned from 15 P-type ATPases differing in cation specificity and evolutionary distance from PMA1.

As shown in Fig. 1, there is a striking stretch of identity from Asp-378 through Thr-382; the 5-amino acid motif DKTGT is conserved in every known P-type ATPase. On either side of this motif, there are two residues (Cys-376 and Ser-377; Leu-383 and Thr-384) that are nearly invariant, except in the distantly related heavy metal pumps and the KdpB potassium pump from Escherichia coli. Further downstream, conservation falls off sharply after Thr-384. Upstream of Cys-376, there is still noticeable conservation at Leu-375, which is present in all known H+-ATPases and is replaced by Ile or Val in the other P-type enzymes, and at Ile-374, which is replaced by Val or Leu in many P-ATPases (but by Ala, Ser, or Thr in other members of the family). Interestingly, the Robson-Garnier algorithm (29) predicts a beta -turn in the phosphorylation region; the turn begins at Ser-377, continues to Asn-386, and except for a brief indeterminate stretch immediately following Asn-386, is flanked by sequences that are strongly alpha -helical in character (Fig. 1).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   Alignment of the phosphorylation region in P-ATPases. A, amino acid sequences of 48 residues surrounding the catalytic phosphorylation site were aligned using the Pileup program of the University of Wisconsin Genetics Computer Group (GCG). The enzymes were divided into five groups depending on cation specificity: 1) fungal, algal, and plant H+-ATPases; 2) bacterial Mg2+-ATPases; fungal and plant Ca2+-ATPases; 3) mammalian Ca2+-, Na+,K+-, and gastric H+,K+-ATPases; 4) heavy metal transporting P-ATPases; 5) the E. coli K+-ATPase. Residues that are conserved in all known P-ATPases are boxed. From top to bottom of the figure, GCG accession numbers for the sequences are XO3534, P54210, P20649, U07843, M25488, M96324, M12898, X63575, P20648, P05023, L10909, L13292, U03464, L06133, and P03960. B, the Robson-Garnier secondary structure prediction for PMA1 was determined using the GCG PeptideStructure program. Residues likely to contribute to alpha -helices are indicated by H, beta -turns by T, and those of indeterminate nature by dots.

Mutagenesis, Expression in Secretory Vesicles, and Enzymatic Activity-- Based on the alignment of Fig. 1, we carried out alanine-scanning mutagenesis from Ile-374 to Thr-384. Because it seemed likely that at least some of the Ala substitutions would be lethal (15-17, 22), a transient expression system (19) was used for the initial set of experiments. Expression was switched from the wild-type ATPase gene, located on the chromosome and controlled by the GAL1 promoter, to a mutant allele, located on a centromeric plasmid and controlled by a heat-shock promoter. At the same time, a temperature-sensitive block (sec6-4) in the last step of the secretory pathway led to the accumulation of secretory vesicles in the cytoplasm. It was then possible to isolate the vesicles and assay by immunoblotting with anti-ATPase antibody for newly synthesized mutant protein en route to the plasma membrane.

As shown in Table II, the expression levels of C376A (104%), S377A (103%), and G381A (81%) were essentially normal when compared with the wild-type control. However, expression was significantly reduced in the rest of the mutants: I374A (55%), L375A (31%), K379A (29%), T380A (20%), T382A (14%), L383A (12%), and T384A (9%). D378A was the most severely affected, with little or no ATPase present in the secretory vesicles (5%) compared with an empty-plasmid control (2%). In a companion experiment, total cellular membranes were isolated and examined by immunoblotting, as shown in Fig. 2. In this case, all of the mutant proteins could be seen at roughly normal levels 30 min after the temperature shift, and the amount did not change significantly after 90 min (data not shown). Thus, there was no apparent defect in either the synthesis or the short term stability of the mutant ATPases; rather, as reported earlier for other substitutions at Asp-378 (15-17, 22), the failure of many of the Ala mutants to reach the secretory vesicles reflects a problem in their trafficking to the cell surface.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of mutations in the phosphorylation region on expression and ATP hydrolysis


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 2.   Steady-state expression levels of wild-type and mutant ATPases in total yeast membranes. SY4 cells transformed with YCp2HSE-PMA1-myc encoding Myc-tagged PMA1, or with related plasmids encoding each of the mutant enzymes, were grown in galactose medium at 23 °C as described under "Experimental Procedures," shifted to glucose medium to turn off expression of the chromosomal ATPase gene, and then shifted to 38 °C for 30 min to induce expression of the plasmid-encoded, Myc-tagged wild-type (WT) and mutant ATPases. Total membranes were isolated, subjected to SDS-PAGE (10 µg of protein/lane), immunoblotted with the c-Myc antibody, and detected by 125I-protein A and autoradiography.

ATP hydrolysis was also severely affected in most of the mutants (Table II). Among those examined, only C376A displayed near-normal activity (94%), while much lower values (9-29%) were seen in I374A, L375A, S377A, K379A, and G381A. The remaining mutants had activities that were not significantly above background.

Subcellular Location of the Mutant ATPases-- To examine the trafficking defects in greater detail, a different expression strategy was used, coupled with indirect immunofluorescence to visualize the location of the mutant ATPases. In this case, each Myc-tagged mutant allele was placed under GAL1 control on a centromeric plasmid and transformed into yeast strain NY605, which contains a wild-type copy of PMA1 on the chromosome. Expression of the mutant protein was induced by growth on galactose medium, and the cells were examined by immunofluorescence microscopy using c-Myc antibody.

Once again, the mutants displayed a range of behavior (Fig. 3). In C376A, S377A, and G381A, there was a smooth, ringlike labeling of the plasma membrane by c-Myc antibody, and little if any epitope-tagged ATPase was seen intracellularly; this was also the case for the wild-type control. By contrast, in I374A, L375A, T382A, and L383A, the Myc-tagged ATPase was distributed to varying degrees between the plasma membrane and intracellular structures. Finally, there were mutants (D378A, K379A, T380A, and T384A) in which the Myc-tagged ATPase appeared only intracellularly; in these cells, no smooth labeling of the plasma membrane was observed.


View larger version (86K):
[in this window]
[in a new window]
 
Fig. 3.   Subcellular localization of wild-type and mutant ATPases as revealed by immunofluorescence microscopy. NY605 cells were transformed with plasmids that encode Myc-tagged wild-type (WT), C376A, I374A, or D378A ATPase, grown to early log phase in medium containing 4% raffinose, and transferred to medium containing 4% galactose to induce expression of the plasmid-encoded ATPase. After 4 h of induction, the cells were fixed with formaldehyde and processed for immunofluorescence using anti-c-Myc monoclonal antibody (9E10.2) and Texas Red-conjugated goat anti-mouse IgG, as described under "Experimental Procedures." For each mutant, the same field of cells was photographed by bright field optics (top), by UV light to detect DNA after staining with 4,6'-diamidino-2-phenylindole (DAPI), and by indirect immunofluorescence to detect pma1-myc (MYC). The bottom panels show uninduced control cells that were stained for immunofluorescence in parallel.

It seemed likely that the intracellular structures were derived, at least in part, from the endoplasmic reticulum. The yeast ER typically surrounds the nucleus, with extensions to the cell periphery (30). During the expression of abnormal proteins, however, it can proliferate into enlarged structures (31) that are labeled by antibody against the lumenal ER protein, Kar2 (32-34). Indeed, Harris et al. (16) and Portillo (17) have recently reported such proliferation in cells expressing certain mutant forms of PMA1 ATPase, including D378N and D378E. Thus, an important goal of the present study was to determine whether any or all of the current group of mutant ATPases accumulate in these ER-derived structures, and at the same time, whether there is also accumulation in other intracellular compartments such as the Golgi.

To address these questions, double-labeling immunofluorescence and confocal microscopy were carried out on cells expressing mutant PMA1 ATPases of the second, "intermediate" type and the third, severely affected type. In addition to c-Myc antibody, which labeled the epitope-tagged mutant ATPases, Kar2 antibody served as a marker for the ER (26) and Sec7 antibody, for the Golgi (25). In the case of I374A (an intermediate mutant), some of the ATPase reached the plasma membrane (Fig. 4A). However, much of it co-localized with Kar2 in the perinuclear region and in brightly staining cytoplasmic structures, reminiscent of those described by Harris et al. (16); the regions of co-localization appear as yellow and orange areas on the merged image of panel A/B. In the more than 20 cells that were closely examined, I374A was not detected in the Sec7-containing compartment, even when large amounts of I374A were seen in both the plasma membrane and ER (Fig. 4, C, D, and C/D). Thus, there did not appear to be a uniform slowing of transit through the entire secretory pathway; rather, I374A ATPase that managed to leave the ER could move all the way to the cell surface. Similar observations were made for each of the other intermediate mutants including L375A, T382A, and L383A. In severely affected mutants such as D378A, there was no evidence of epitope-tagged ATPase at the plasma membrane or in the Golgi (Fig. 4G/H); rather, staining was limited to the Kar2-containing cytoplasmic structures (Fig. 4E/F).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 4.   Retention of biogenesis-defective mutant ATPases in intracellular structures derived from the ER. NY605 cells were transformed with centromeric plasmids encoding GAL1pr-I374A-myc (panels A-D), and GAL1pr-D378A-myc (panels E-H) and grown to early log phase in medium containing 4% raffinose. Expression of the Myc-tagged ATPase was induced by shifting to medium containing 4% galactose. The cells were then fixed with formaldehyde and processed for double-label immunofluorescence as described under "Experimental Procedures," using antiserum to c-Myc (9E10.2), combined with antiserum to either Kar2 (panels A, B, E, and F) or Sec 7 (panels C, D, G, and H), and detected by FITC- and Texas Red-conjugated secondary antibodies. Staining of both fluorochromes was visualized simultaneously by confocal microscopy using dual channel filters, and the images were merged (A/B, C/D, E/F, G/H) using Adobe Photoshop. Bar = 5 µm.

Protein Folding as Studied by Limited Trypsinolysis-- In previous work, we have shown that D378N ATPase is integrated into the lipid bilayer but is poorly folded, with greatly increased sensitivity to trypsin (18); it is presumably the folding defect that causes the ATPase to be retained in the ER (15-17). As described above, the present study now provides evidence for a spectrum of trafficking problems in mutants throughout the phosphorylation region of the ATPase. Some, like D378A, display virtually complete ER retention; in other cases, from 10% to 100% of the protein can travel to the secretory vesicles and then to the cell surface. It was thus interesting to determine whether the severity of the trafficking problem might correlate with the extent of the protein folding defect, as judged by limited trypsinolysis.

For this set of experiments, total 35S-labeled membranes containing each of the mutant ATPases were digested with trypsin, and the resulting cleavage products were isolated by immunoprecipitation with ATPase antibody and analyzed by SDS-PAGE and autoradiography. Indeed, the mutants varied in their sensitivity to limited trypsinolysis, as shown in Fig. 5. Some (C376A and S377A) were virtually indistinguishable from the wild-type control; after 5 min of digestion at a trypsin:protein ratio of 1:20, there were roughly equal amounts of full-length 100-kDa ATPase and a 97-kDa fragment. Others (I374A and G381A) displayed intermediate behavior; after 5 min of digestion, both 100- and 97-kDa bands were still visible, but in significantly reduced amounts. By contrast, most (L375A, D378A, K379A, T380A, T382A, L383A, and T384A) were extremely sensitive to trypsinolysis; after as little as 1 min of digestion, the 100- and 97-kDa species had been almost completely degraded and were barely perceptible by autoradiography. Thus, there was a rough correlation between poor protein folding and intracellular retention of the mutant ATPase; the apparent exceptions will be discussed below.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   Time course of trypsinolysis of wild-type and mutant ATPases. Secretory vesicles (10 µg of protein) containing [35S]methionine-labeled wild-type (WT), S377A, D378A, K379A, G381A, or L383A ATPase were incubated at a trypsin:protein ratio of 1:20 for 0, 1, and 5 min. Samples were immunoprecipitated with anti-ATPase antibody and analyzed by SDS-PAGE and fluorography.

Effect on Co-expression of Wild-type ATPase-- As described previously, mutations at the phosphorylation site (Asp-378) of PMA1 have a dominant negative phenotype; they are lethal when co-expressed with the wild-type allele (15-17). It was therefore of interest to survey the genetic behavior of mutations across the phosphorylation region. For this purpose, the cells used for the immunofluorescence experiments of Figs. 3 and 4 were plated on galactose or glucose medium to induce or repress expression of the mutant allele. As shown in Fig. 6, the various mutations exerted a range of effects on cell growth. At one extreme, D378A, K379A, T380A, and T384A displayed a dominant negative phenotype, with D378A inhibiting growth on galactose most severely. I374A, L375A, G381A, T382A, and L383A had an intermediate effect, slowing but not completely preventing growth on galactose, and C376A and S377A were recessive, growing on galactose as well as the wild-type and empty vector controls. Thus, with one exception (G381A, which will be discussed below), mutant ATPases with trafficking defects were either partially or completely dominant in the growth test.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 6.   Growth of strains co-expressing mutant and wild-type ATPases. NY605 cells, containing a constitutively expressed chromosomal copy of the PMA1 gene, were transformed with either GAL1-YCplac33 (Empty plasmid), GAL1pr-PMA1-myc gene (PMA1), or GAL1pr-pma1-myc (mutant listed) as described under "Experimental Procedures." Drops of each diluted strain were placed onto synthetic medium containing 2% galactose (Gal) or 2% glucose (Glu), grown for 42 h at 30 °C, and photographed.

To determine whether, as expected, the co-expressed mutant and wild-type ATPases were trapped in the same intracellular compartment, mutant and wild-type alleles were epitope-tagged (with c-Myc and HA, respectively), placed behind the GAL1 promoter on separate plasmids, and transformed together into NY605 cells. An example of this experiment using a mutant with an intermediate block in biogenesis (L383A) is shown in Fig. 7 (bottom panel). When cells containing L383A and wild-type plasmids were shifted to galactose medium and examined by immunofluorescence, there was co-localization of newly synthesized mutant and wild-type ATPases in perinuclear and peripheral intracellular structures, as revealed in the yellow and yellow-orange regions of the merged images. Combining this observation with the results of Fig. 3, we conclude that the two forms of the ATPase were arrested together in the ER-derived membranes. In contrast, when recessive mutants such as C376A were co-expressed with the wild type, both ATPases reached the cell surface (Fig. 7, top panel).


View larger version (103K):
[in this window]
[in a new window]
 
Fig. 7.   Co-localization of biogenesis-defective mutant ATPases with wild-type ATPase in the ER. NY605 cells were transformed with a centromeric plasmid encoding HA-tagged wild-type ATPase (GAL1pr-PMA1-HA), in combination with a similar plasmid encoding either myc-tagged C376A (GAL1pr-C376A-myc, top panel), or Myc-tagged L383A (GAL1pr-L383A-myc, bottom panel), as described under "Experimental Procedures." Cells were grown to early log phase in uracil- and leucine-free medium containing 4% raffinose, and then shifted to medium containing 4% galactose to induce expression of the plasmid-encoded ATPases. The cells were fixed with formaldehyde and processed for double-label immunofluorescence as described under "Experimental Procedures," using antisera to c-Myc (left panels) and HA (middle panels), and detected by Texas Red- and FITC-conjugated secondary antibodies, respectively. Staining of both fluorochromes was visualized simultaneously by confocal microscopy using dual channel filters, and the images were merged (right panels) using Adobe Photoshop. Bar = 5 µm.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

As described in the Introduction, the starting point for this study was the discovery that mutations at position Asp-378 cause misfolding of the yeast PMA1 ATPase, leading to retention in the ER and dominant lethality (15-17). One goal of the present work was to learn whether these features are specific to Asp-378 or whether they are shared by other residues throughout the phosphorylation region. It is now clear that the latter is the case; 8 of 11 alanine substitutions in the stretch between Ile-374 and Thr-384 caused noticeable defects in folding and biogenesis, resulting in some degree of dominant lethality. By contrast, similar problems have been seen in only 6 out of 48 site-directed mutants in the adjacent stalk3 and M4 regions of PMA1 (28). Based on these findings, the local sequences surrounding Asp-378 must play a special role in ATPase maturation and transport to the cell surface.

When looked at in detail, mutants in the phosphorylation region can be arrayed along a continuum based on their behavior during biogenesis (Table III). Some of the mutant proteins (C376A, S377A, G381A) travel normally along the secretory pathway as evidenced by either of two independent assays: immunoblotting of ATPase that has reached the secretory vesicles (in the sec6-4 expression system; Ref. 19) or indirect immunofluorescence of ATPase in the plasma membrane of intact cells (after epitope-tagging and expression in strain NY605). Not surprisingly, these mutant ATPases appear to be either normally folded (C376A, S377A) or reasonably well folded (G381A) when tested by limited trypsinolysis. It is worth pointing out that two of the three mutants, S377A and G381A, are virtually inactive; rates of ATP hydrolysis, assayed in isolated secretory vesicles, were only 7-15% of the wild-type control (before correction for expression), implying that delivery of the ATPase to the secretory vesicles does not require PMA1-mediated proton transport into the compartments of the secretory pathway.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Summary of the effects of mutations in the phosphorylation region

At the other end of the continuum lie two mutants (D378A and T384A) with very severe blocks in biogenesis. Both were virtually absent from isolated secretory vesicles, and both were seen only in ER-derived structures upon indirect immunofluorescence of intact cells. Based on their extreme sensitivity to trypsinolysis, these two mutant ATPases appear to be poorly folded; it therefore seems likely that they are retained intracellularly by a quality control mechanism at the ER-to-Golgi step of the secretory pathway.

The remaining six mutants were intermediate in their behavior, exhibiting a range of abilities (between 55% and 12%) to reach the secretory vesicles in the sec6-4 system. Four of them (I374A, L375A, T382A, L383A) also showed intermediate subcellular localization based on indirect immunofluorescence microscopy; some ATPase clearly reached the cell surface, but much of it remained in ER-derived intracellular structures. In the other two mutants (K379A and T380A), the epitope-tagged ATPase appeared to be largely, if not completely, arrested in the ER. Structurally, one member of this group (I374A) was intermediate in its sensitivity to trypsin and the rest were highly sensitive, again pointing to abnormalities in protein folding.

It is intriguing that ATPase biogenesis is so vulnerable to substitutions in the phosphorylation region. Previous studies have shown that the spacing of residues in this part of the protein is critically important, since the insertion of a single glycine at successive points between Cys-376 and Thr-384 leads to biosynthetic arrest of the ATPase (22). When the mutational data are superimposed upon secondary structural predictions for the phosphorylation region, there is a clear correspondence between the cluster of biogenesis-defective mutations and a predicted beta -turn in the vicinity of Asp-378. According to the same algorithm (29), substitution by alanine at each position should introduce a more helical nature to the beta -turn (data not shown) and could therefore perturb the structure of the cytoplasmic mid-region of the ATPase, preventing insertion of the C-terminal transmembrane domains into the lipid bilayer. Indeed, it has been shown that beta -turns play a major role in defining the three-dimensional organization of many proteins (35) and that mutations in beta -turns may have a special propensity to disrupt the formation of folding intermediates (36, 37).

Based on the current view of protein folding, it seems plausible that the ER-retained ATPases exist in a dynamic equilibrium between intermediate and mature folded states, as proposed for Delta F508 CFTR (38), with the more severe mutations causing kinetic traps that favor non-productive or off-pathway folding intermediates. According to this model, the population of mutant protein that attains normal conformation can exit the ER, while the malfolded forms are retained. It may be significant that the trypsin-sensitive mutant ATPases, particularly D378A, are generally more prone to aggregation on SDS-PAGE than well folded ATPases such as C376A, S377A, and G381A (data not shown). At the moment, it is unclear whether the mutants capable of reaching the plasma membrane are malfolded forms that escape the ER quality control machinery, or whether some proportion of the mutant proteins eventually manage to fold correctly; our observation of a trypsin-resistant subpopulation of I374A that reaches secretory vesicles lends support to the latter possibility. Severe biogenesis mutants such as D378A are probably incapable of achieving correct conformation and for this reason undergo complete biosynthetic arrest.

Finally, it is interesting to speculate on the mechanism by which dominant lethal ATPase mutants cause co-expressed wild-type ATPase to be retained in the ER (Refs. 16 and 17; this study). One obvious possibility is that the mutant protein forms aggregates (42), leading to a general disruption of ER function. At first glance, this idea fits with the striking proliferation of ER membranes that takes place during overexpression of the closely related PMA2 ATPase (32), H+-ATPases from higher plants (39), and the integral ER proteins hydroxymethylglutaryl-coenzyme A reductase (31) and cytochrome b5 (40). As reviewed by Kerchove et al. (41), the morphology of the proliferated ER can vary, depending on the expressed protein, but in all cases is thought to occur as the cell's response to increased levels of these proteins in the ER.

However, although expression of the dominant lethal PMA1 mutants clearly disrupts the morphology of the ER membranes, there does not appear to be a complete block in ER function that would explain the retention of the wild-type ATPase. This point was shown in a recent study in which secretory vesicles, isolated from cells producing the D378N ATPase, contained a normal profile of Coomassie-stained proteins (18), suggesting that the biosynthetic block is limited to the ATPase or a small subset of secretory proteins. Two explanations have been proposed for the seeming specificity of the block (16, 41). First, the wild-type ATPase may form oligomers with malfolded mutant ATPase, resulting in the retention of both. Second, the wild-type ATPase may become arrested intracellularly due to the abnormal binding of co-expressed mutant ATPase with some component of the ER biosynthetic machinery, such as a translocation channel or a chaperone.

It is interesting to examine the entire set of phosphorylation region mutants in the light of these two hypotheses. In general, as described above, there was a clear correspondence between the amount of mutant ATPase retained in the ER and the severity of the dominant lethal phenotype. However, an interesting exception to this rule was G381A, which, although not retained in the ER, was inactive, slightly misfolded, and exerted an inhibitory effect on cell growth when expressed with wild type. It is possible that this mutant is folded well enough to bypass the ER quality control machinery, but interferes with the functioning of the wild-type ATPase at the plasma membrane, perhaps by forming non-functional oligomers.

Overall, this study points to the complex and critical nature of the region surrounding Asp-378 for biogenesis and folding of the ATPase. It also calls attention to the quality control mechanisms that govern the exit of the ATPase from the ER, and suggests that further analysis of those mechanisms will be fruitful. The recent finding of several new genes affecting ATPase biogenesis and stability (43-45) will serve as a useful point of departure for such analysis.

    ACKNOWLEDGEMENTS

We thank Drs. Henrik Dohlman for providing the c-Myc monoclonal antibody and for advice on yeast immunofluorescence, Robert Nakamoto for supplying the pRN93 and pRN94 expression vectors, Philippe Mâle for assistance with confocal microscopy and photomicrographs, Michael Caplan and Vincent Marchesi for the use of their microscopes, and Anita Panek for support throughout this study. We are also grateful to Drs. Mark Rose and Randy Schekman for generously providing the Kar2 and Sec7 antibodies, respectively.

    FOOTNOTES

* This work was supported by National Institutes of Health Research Grant GM15761 (to C. W. S), National Institutes of Health Postdoctoral Fellowship GM18623 (to N. D. D.), and a fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (to C. F. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Genetics, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06510. Tel.: 203-785-2690; Fax: 203-785-7227.

§ Current address: Universidade Federal do Rio de Janeiro, Instituto de Quimica-Departamento de Bioquimica, Ilha do Fundao, Rio de Janeiro, Brazil CEP 21949-900.

The abbreviations used are: CFTR, cystic fibrosis transmembrane conductance regulator; ER, endoplasmic reticulum; HA, influenza hemagglutininPAGE, polyacrylamide gel electrophoresisFITC, fluorescein isothiocyanate.

2 C. F. Tourinho dos Santos, N. D. DeWitt, K. E. Allen, and C. W. Slayman, manuscript in preparation.

3 A. Ambesi, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Gething, M.-J., and Sambrook, J. (1992) Nature 355, 33-45[CrossRef][Medline] [Order article via Infotrieve]
  2. Hammond, C., and Helenius, A. (1995) Curr. Opin. Cell Biol. 7, 523-529[CrossRef][Medline] [Order article via Infotrieve]
  3. Brooks, D. A. (1997) FEBS Lett. 409, 115-120[CrossRef][Medline] [Order article via Infotrieve]
  4. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., and Smith, A. E. (1990) Cell 63, 827-834[Medline] [Order article via Infotrieve]
  5. Riordan, J. R. (1993) Annu. Rev. Physiol. 55, 609-630[CrossRef][Medline] [Order article via Infotrieve]
  6. Welsh, M. J., and Smith, A. E. (1993) Cell 73, 1251-1254[Medline] [Order article via Infotrieve]
  7. Leitersdorf, E., Hobbs, H. H., Fourie, A. M., Jacobs, M., van der Westhyzen, D. R., and Coetzee, G. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7912-7916[Abstract]
  8. Djordjevic, J. T., Bierli, S., Smith, R., and Kroon, P. A. (1996) Eur. J. Biochem. 239, 214-219[Abstract]
  9. Jensen, H. K., Holst, H., Jensen, L. G., Jørgensen, M. M., Andreasen, P. H., Jensen, T. G., Andresen, B. S., Heath, F., Hansen, P. S., Neve, S., Kristiansen, K., Færgeman, O., Kølvraa, S., Bolund, L., and Gregersen, N. (1997) Atherosclerosis 131, 67-72[CrossRef][Medline] [Order article via Infotrieve]
  10. Schekman, R. (1992) Curr. Opin. Cell Biol. 4, 587-92[Medline] [Order article via Infotrieve]
  11. Serrano, R., Kielland-Brandt, M. C., and Fink, G. R. (1986) Nature 319, 689-693[Medline] [Order article via Infotrieve]
  12. Rao, R., and Slayman, C. W. (1996) in The Mycota (Brambl, R., and Marzluf, G. A., eds), Vol. 3, pp. 29-56, Springer-Verlag, Berlin
  13. Mandala, S. M., and Slayman, C. W. (1989) J. Biol. Chem. 264, 16276-16281[Abstract/Free Full Text]
  14. Seibert, F. S., Linsdell, P., Loo, T. W., Hanrahan, J. W., Clarke, D. M., and Riordan, J. R. (1996) J. Biol. Chem. 271, 15139-45[Abstract/Free Full Text]
  15. Rao, R., Nakamoto, R. K., Verjovski-Almedia, S., and Slayman, C. W. (1992) Ann. N. Y. Acad. Sci. 671, 195-203[Medline] [Order article via Infotrieve]
  16. Harris, S. L., Na, S., Zhu, X., Seto-Young, D., Perlin, D. S., Teem, J. H., and Haber, J. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10531-10535[Abstract/Free Full Text]
  17. Portillo, F. (1997) FEBS Lett. 402, 136-140[CrossRef][Medline] [Order article via Infotrieve]
  18. Nakamoto, R. K., Verjovski-Almeida, S., Allen, K. E., Ambesi, A., Rao, R., and Slayman, C. W. (1998) J. Biol. Chem. 273, 7338-7344[Abstract/Free Full Text]
  19. Nakamoto, R. K., Rao, R., and Slayman, C. W. (1991) J. Biol. Chem. 266, 7940-7949[Abstract/Free Full Text]
  20. Goff, C. G., Moir, D. T., Kohno, T., Gravius, T. C., Smith, R. A., Yamasaki, E., and Taunton-Rigby, A. (1984) Gene (Amst.) 27, 35-46[CrossRef][Medline] [Order article via Infotrieve]
  21. Ito, H., Fukuda, Y., Murata, K., and Kimura, A. (1983) J. Bacteriol. 153, 163-168[Medline] [Order article via Infotrieve]
  22. Rao, R., and Slayman, C. W. (1993) J. Biol. Chem. 268, 6708-6713[Abstract/Free Full Text]
  23. Redding, K., Holcomb, C., and Fuller, R. S. (1991) J. Cell Biol. 113, 527-538[Abstract]
  24. Rose, M. D., Winston, F., and Heiter, P. (1990) Methods in Yeast Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  25. Franzusoff, A., Redding, K., Crosby, J., Fuller, R. S., and Schekman, R. (1991) J. Cell Biol. 112, 27-37[Abstract]
  26. Rose, M. D., Misra, L. M., and Vogel, J. P. (1989) Cell 57, 1211-21[Medline] [Order article via Infotrieve]
  27. Ambesi, A., Allen, K. E., and Slayman, C. W. (1997) Anal. Biochem. 251, 127-129[CrossRef][Medline] [Order article via Infotrieve]
  28. Ambesi, A., Pan, R. L., and Slayman, C. W. (1996) J. Biol. Chem. 271, 22999-23005[Abstract/Free Full Text]
  29. Garnier, J., Osguthorpe, D. J., and Robson, B. (1978) J. Mol. Biol. 120, 97-120[Medline] [Order article via Infotrieve]
  30. Preuss, D., Mulholland, J., Kaiser, C. A., Orlean, P., Albright, C., Rose, M. D., Robbins, P. W., and Botstein, D. (1991) Yeast 7, 891-911[Medline] [Order article via Infotrieve]
  31. Wright, R., Basson, M., D'Ari, L., and Rine, J. (1988) J. Cell Biol. 130, 29-39[Abstract]
  32. Supply, P., Wach, A., Thines-Sempoux, D., and Goffeau, A. (1993) J. Biol. Chem. 268, 19744-19752[Abstract/Free Full Text]
  33. Wiedmann, B., Silver, P., Schunck, W.-H., and Wiedmann, M. (1993) Biochim. Biophys. Acta 1153, 267-276[Medline] [Order article via Infotrieve]
  34. Kölling, R., and Hollenberg, C. P. (1996) Eur. J. Biochem. 239, 356-361[Abstract]
  35. Rose, G. L., Gierasch, L. M., and Smith, J. (1985) Adv. Protein Chem. 37, 1-109[Medline] [Order article via Infotrieve]
  36. Villafane, R., and King, J. (1988) J. Mol. Biol. 204, 607-619[Medline] [Order article via Infotrieve]
  37. Yu, M.-H., and King, J. (1988) J. Biol. Chem. 263, 1424-1431[Abstract/Free Full Text]
  38. Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X.-B., Riordan, J. R., and Grinstein, S. (1994) EMBO J. 13, 6076-6086[Abstract]
  39. Villalba, J. M., Palmgren, M. G., Berberian, G. E., Ferguson, C., and Serrano, R. (1992) J. Biol. Chem. 267, 12341-12349[Abstract/Free Full Text]
  40. Vergeres, G., Yen, T. S. B., Aggeler, J., Lausier, J., and Waskell, L. (1993) J. Cell Sci. 106, 249-259[Abstract/Free Full Text]
  41. Kerchove d'Exaerde, A. D., Supply, P., and Goffeau, A. (1996) Yeast 12, 907-916[CrossRef][Medline] [Order article via Infotrieve]
  42. Marquardt, T., and Helenius, A. (1992) J. Cell Biol. 117, 505-513[Abstract]
  43. Na, S., Hincapie, M., McCusker, J. H., and Haber, J. E. (1995) J. Biol. Chem. 270, 6815-6823[Abstract/Free Full Text]
  44. Chang, A., and Fink, G. R. (1995) J. Cell Biol. 128, 39-49[Abstract]
  45. Luo, W., and Chang, A. (1997) J. Cell Biol. 138, 731-746[Abstract/Free Full Text]
  46. Geitz, R. D., and Sugino, A. (1988) Gene (Amst.) 74, 527-534[CrossRef][Medline] [Order article via Infotrieve]
  47. Petrov, V. V., and Slayman, C. W. (1995) J. Biol. Chem 270, 28535-28540[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.